Shots:
argenx has reported the topline P-II (FB102-301) trial results assessing FB102 (2 IV infusions) vs PBO in 126 adults with celiac disease who were symptom free on a strict gluten-free diet for at least 12mos.
The trial met its 1EP, showing improvement in the Vh:Cd ratio in pts undergoing a gluten challenge. Improvements in…
